详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

108| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China [2]Department of Oncology,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China.

出处：

DOI：

ISSN：

关键词： NSCLC Immunotherapy Biomarkers Anti-PD-1 PD-L1 therapy Efficacy prediction

摘要：

Immunotherapy, especially anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) treatment has significantly improved the survival of non-small cell lung cancer (NSCLC) patients. However, the overall response rate remains unsatisfactory. Many factors affect the outcome of anti-PD-1/PD-L1 treatment, such as PD-L1 expression level, tumor-infiltrating lymphocytes (TILs), tumor mutation burden (TMB), neoantigens, and driver gene mutations. Further exploration of biomarkers would be favorable for the best selection of patients and precisely predict the efficacy of anti-PD-1/PD-L1 treatment. In this review, we summarized the latest advances in this field, and discussed the potential applications of these laboratory findings in the clinic.

基金：

基金编号： 81874120 82073370

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 3 区医学

小类 | 3 区血液学 3 区肿瘤学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区血液学 2 区肿瘤学

JCR分区：

出版当年[2019]版：

Q2 HEMATOLOGY Q2 ONCOLOGY

最新[2023]版：

Q1 HEMATOLOGY Q1 ONCOLOGY

影响因子： 9.4 最新[2023版] 8.3 最新五年平均 3.492 出版当年[2019版] 0 出版当年五年平均 0 出版前一年[2018版] 5.133 出版后一年[2020版]

第一作者：

第一作者单位： [1]Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China [2]Department of Oncology,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China.

共同第一作者：

通讯作者：

通讯机构： [1]Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China [2]Department of Oncology,Tongji Hospital of Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy [2]Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy [3]Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis [4]A brief report on incidence, radiographic feature and prognostic significance of brain MRI changes after anti-PD-1/PD-L1 therapy in advanced non-small cell lung cancer [5]A brief report on incidence, radiographic feature and prognostic significance of brain MRI changes after anti-PD-1/PD-L1 therapy in advanced non-small cell lung cancer. [6]SRSF10 facilitates HCC growth and metastasis by suppressing CD8+T cell infiltration and targeting SRSF10 enhances anti-PD-L1 therapy [7]Sitravatinib plus tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC [8]Platelet membrane camouflaged AIEgen-mediated photodynamic therapy improves the effectiveness of anti-PD-L1 immunotherapy in large-burden tumors [9]Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation [10]Impact of COVID-19 vaccination on the use of anti-PD-1 immunotherapy in cancer patients